Want to see SE:ANNX full AI Analyst Report?
Top Page
Annexin Pharmaceuticals AB
(ANNX)
Select Model
Select Model
Rating:41Neutral
Price Target:
kr8.50
▼(-37.73% Downside)
Action:Reiterated
Date:09/22/26
The score is driven primarily by weak financial performance (no revenue, large recurring losses, and sustained cash burn with shrinking equity), indicating elevated funding and dilution risk. Technicals reinforce the downside picture with a clear downtrend and weak momentum, while valuation is constrained by a negative P/E and no dividend yield support.
Positive Factors
Debt-free balance sheet
The absence of reported debt removes interest expense and near-term debt-servicing pressure, giving the company greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued development activity while reducing creditor-related balance-sheet risk.
Negative Factors
No revenue generation
The absence of reported revenue means the company currently lacks an operating commercial base to fund research and development internally. Progress therefore depends heavily on clinical and regulatory outcomes, while future commercialization remains unproven and uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
The absence of reported debt removes interest expense and near-term debt-servicing pressure, giving the company greater financial flexibility than a similarly loss-making biotech with leverage. This supports continued development activity while reducing creditor-related balance-sheet risk.
Read all positive factors
Annexin Pharmaceuticals AB (ANNX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr78.11M
Dividend YieldN/A
Average Volume (3M)12.12K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue GrowthN/A
EPS Growth13.53%
CountrySE
Employees4
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,718,182
10 Day Avg. Volume21,778
30 Day Avg. Volume12,121
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.25
Price to Sales (P/S)0.00
P/FCF Ratio-3.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Annexin Pharmaceuticals AB Business Overview & Revenue Model
Company Description
Annexin Pharmaceuticals AB (publ), a clinical stage biotechnology company, develops drug candidates for the treatment of various cardiovascular diseases. It develops ANXV, a human recombinant protein and Annexin A5, natural protein that protects a...
Annexin Pharmaceuticals AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -48.00K | -48.00K | -193.00K | -193.00K | -193.00K | -192.00K |
| EBITDA | -41.97M | -36.84M | -50.20M | -43.86M | -40.72M | -50.28M |
| Net Income | -42.49M | -36.89M | -50.25M | -44.05M | -40.73M | -52.14M |
Balance Sheet | ||||||
| Total Assets | 7.99M | 30.16M | 19.04M | 26.76M | 36.68M | 52.79M |
| Cash, Cash Equivalents and Short-Term Investments | 5.27M | 27.39M | 16.34M | 21.41M | 31.11M | 49.48M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 5.47M | 5.22M | 5.32M | 7.95M | 6.53M | 6.06M |
| Stockholders Equity | 2.52M | 24.93M | 13.71M | 18.81M | 30.15M | 46.73M |
Cash Flow | ||||||
| Free Cash Flow | -40.65M | -37.05M | -50.23M | -43.40M | -41.16M | -45.02M |
| Operating Cash Flow | -40.52M | -36.92M | -50.23M | -43.40M | -41.16M | -45.02M |
| Investing Cash Flow | -129.00K | -129.00K | 0.00 | 96.00K | -260.00K | 0.00 |
| Financing Cash Flow | -335.00K | 48.11M | 45.15M | 33.61M | 23.06M | 76.37M |
Annexin Pharmaceuticals AB Technical Analysis
Negative
13.65
Price Trends
12.32
Negative
12.66
Negative
14.18
Negative
Market Momentum
-1.11
Positive
19.46
Positive
7.68
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ANNX, the sentiment is Negative. The current price of 13.65 is above the 20-day moving average (MA) of 11.52, above the 50-day MA of 12.32, and below the 200-day MA of 14.18, indicating a bearish trend. The MACD of -1.11 indicates Positive momentum. The RSI at 19.46 is Positive, neither overbought nor oversold. The STOCH value of 7.68 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ANNX.
Annexin Pharmaceuticals AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | kr396.98M | 2.24 | 63.09% | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
49 Neutral | kr228.72M | -4.59 | -13.41% | ― | -68.66% | -137.27% | |
48 Neutral | kr76.64M | -2.11 | -106.23% | ― | -97.37% | 25.28% | |
43 Neutral | kr1.48B | -3.04 | -99.58% | ― | -87.22% | -70.29% | |
42 Neutral | kr89.52M | -1.22 | -75.51% | ― | 56.06% | 63.95% | |
41 Neutral | kr78.11M | -1.89 | ― | ― | ― | 13.53% |
* General Sector Average
SE:ANNX
Annexin Pharmaceuticals AB
8.82
-18.57
-67.79%
SE:BINV
BioInvent International AB
22.95
-4.10
-15.16%
SE:XBRANE
Xbrane Biopharma AB
11.00
-22.13
-66.79%
SE:BIOVIC.B
Biovica International AB Class B
0.30
-0.31
-50.49%
SE:SPAGO
Spago Nanomedical AB
0.10
-0.03
-23.85%
SE:CANTA
Cantargia AB
1.52
-1.13
-42.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.